RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced full results from the Phase 3 STELLAR trial, which evaluated sotatercept, ...
Merck & Co., Inc. (NYSE:MRK) on Monday announced positive topline results from the Phase 3 HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background ...
Merck Foundation ( the philanthropic arm of Merck KGaA Germany, conducted the 7th Edition of Merck Foundation First Ladies ...
As of September 24, 2024, the average one-year price target for Merck is $142.74/share. The forecasts range from a low of $126.25 to a high of $162.75. The average price target represents an increase ...
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Merck (NYSE:MRK) with a Peer Perform recommendation. As of October 21, 2024, the average one-year price target for Merck ...
In a potential leap forward in the global fight against the pandemic, drugmaker Merck said Friday that its experimental pill for people sick with COVID-19 reduced hospitalizations and deaths by half.
Drugmaker Merck asked U.S. regulators Monday to authorize its pill for treating COVID-19 in what would add an entirely new and easy-to-use weapon to the world’s arsenal against the pandemic. If ...
Offer period extended for sixth time Now runs until May 2 Merck says 67.5 pct of shares tendered (Adds more comment from Merck, background on deal) FRANKFURT, April 18 (Reuters) - German liquid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback